myeloma

Dr Wargo Discusses Gut Microbiota Signatures and Toxicity Link to Combined CTLA-4, PD-1 in Melanoma

07/19/2021

Jennifer Wargo, MD, professor of Genomic Medicine and Surgical Oncology at The University of Texas MD Anderson Cancer Center, discusses treatment with combined immune checkpoint blockade (CICB) targeting CTLA-4 and PD-1 is associated with...

Jennifer Wargo, MD, professor of...

07/19/2021

Oncology

News

DRd Improves PROs Compared With Rd for Newly Diagnosed MM

02/01/2021

Journal of Clinical Pathways

Transplant Still Preferred Treatment Choice in Young Patients With Myeloma

05/31/2016

JCP Editors

Autologous stem cell transplantation (ASCT) is still the preferred treatment of choice for patients under the age of 65 years with newly diagnosed multiple myeloma (NDMM), according to early results from a phase 3...

...

05/31/2016

Journal of Clinical Pathways